- Home
- RGEN
RGEN
Repligen Corporation
as of 12-09-2025 3:44pm EST
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.
| Founded: | 1981 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 8.2B | IPO Year: | N/A |
| Target Price: | $170.90 | AVG Volume (30 days): | 797.9K |
| Analyst Decision: | Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.03 | EPS Growth: | N/A |
| 52 Week Low/High: | $102.97 - $182.52 | Next Earning Date: | 10-28-2025 |
| Revenue: | $707,890,000 | Revenue Growth: | 11.74% |
| Revenue Growth (this year): | 17.84% | Revenue Growth (next year): | 12.57% |
AI-Powered RGEN Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Repligen Corporation (RGEN)
Chief Executive Officer
Avg Cost/Share
$170.00
Shares
7,041
Total Value
$1,196,970.00
Owned After
35,898
SEC Form 4
Chief Operating Officer
Avg Cost/Share
$151.21
Shares
2,191
Total Value
$331,301.11
Owned After
21,520
SEC Form 4
Director
Avg Cost/Share
$154.20
Shares
20,000
Total Value
$3,092,278.36
Owned After
88,436
Director
Avg Cost/Share
$156.79
Shares
25,000
Total Value
$3,921,939.67
Owned After
88,436
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Loeillot Olivier | RGEN | Chief Executive Officer | Nov 25, 2025 | Sell | $170.00 | 7,041 | $1,196,970.00 | 35,898 | |
| Bylund James | RGEN | Chief Operating Officer | Nov 18, 2025 | Sell | $151.21 | 2,191 | $331,301.11 | 21,520 | |
| Hunt Anthony | RGEN | Director | Nov 13, 2025 | Sell | $154.20 | 20,000 | $3,092,278.36 | 88,436 | |
| Hunt Anthony | RGEN | Director | Nov 12, 2025 | Sell | $156.79 | 25,000 | $3,921,939.67 | 88,436 |
Compare RGEN vs Leading Stocks
See how RGEN stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "RGEN Repligen Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.